Welcome to our dedicated page for Bellus Health news (Ticker: BLU), a resource for investors and traders seeking the latest updates and insights on Bellus Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bellus Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bellus Health's position in the market.
BELLUS Health Inc. (NASDAQ:BLU) has announced participation in the Jefferies Healthcare Conference from June 8-10, 2022, in New York City. CEO Roberto Bellini will engage in a fireside chat on June 8 at 11:00 a.m. ET. The company focuses on innovative therapies for refractory chronic cough, with its candidate BLU-5937 completing a Phase 2b trial and a Phase 3 program expected to start in H2 2022. Chronic cough affects around 9 million patients in the U.S., highlighting a significant market opportunity for BELLUS Health's therapeutics.
BELLUS Health (NASDAQ: BLU) announced significant updates in its recent press release. The company has scheduled an End-of-Phase 2 meeting with the FDA for June 2022, focusing on the Phase 3 program for BLU-5937, a potential treatment for refractory chronic cough (RCC). BELLUS ended Q1 2022 with US$234 million in cash and reported a net loss of US$14.4 million, a slight improvement from US$15.8 million in the previous year. The company will present at the ATS 2022 International Conference, showcasing data from the Phase 2b SOOTHE trial.
BELLUS Health (NASDAQ: BLU) announced the presentation of three late-breaking abstracts from its Phase 2b SOOTHE trial at the ATS 2022 International Conference in San Francisco from May 13-18, 2022. The abstracts will cover safety, efficacy, and responder analyses related to BLU-5937 for refractory chronic cough (RCC). BELLUS plans to initiate a Phase 3 program in the second half of 2022, addressing a significant unmet need for the estimated 9 million RCC patients in the U.S. Currently, no specific therapy is approved for this condition.
BELLUS Health, a clinical-stage biopharmaceutical company focused on novel therapeutics for refractory chronic cough (RCC), announced its participation in multiple investor conferences in May 2022. Events include the Bloom Burton & Co. Healthcare Investor Conference on May 2, the I&I Event by LifeSci Capital on May 10, the RBC Capital Markets Global Healthcare Conference on May 18, and the H.C. Wainwright Global Investment Conference on May 25. BELLUS’s product candidate, BLU-5937, has shown promise in a Phase 2b trial and a Phase 3 program is set to start in late 2022.
BELLUS Health Inc. (Nasdaq: BLU), a clinical-stage biopharmaceutical company, will participate in the Cowen & Co. 42nd Annual Health Care Conference. CEO Roberto Bellini will be on the Respiratory/Infections Panel on March 8, 2022, at 2:10 p.m. ET. The panel discussion will address the company's advancements in treating refractory chronic cough (RCC) and other cough hypersensitivity conditions. Following the event, a recorded webcast will be available on BELLUS Health's website. This aligns with their goal to initiate a Phase 3 program for their product candidate BLU-5937 in late 2022.
BELLUS Health announced positive topline results from its Phase 2b SOOTHE trial for BLU-5937, a potential best-in-class P2X3 antagonist for refractory chronic cough (RCC). The trial demonstrated a 34% placebo-adjusted reduction in cough frequency at day 28. The company plans to seek an End-of-Phase 2 meeting with the FDA in Q2 2022 and initiate Phase 3 studies in the latter half of 2022. As of December 31, 2021, BELLUS had $248.8 million in cash compared to $98.3 million in 2020 but reported a net loss of $71.2 million for 2021 due to increased R&D expenses.
BELLUS Health Inc. (NASDAQ: BLU) has successfully completed a public offering of 25 million common shares at US$8.00 each, generating total gross proceeds of US$200 million. The offering includes an underwriters' option for an additional 3.75 million shares. The funds will be used for research and development, general administrative expenses, and working capital. The offering adheres to regulations in Canada and the United States, having been reported under a prospectus supplement dated December 14, 2021.
BELLUS Health is set to conduct a public offering of 25 million common shares at a price of US$8.00 per share, expected to close on December 17, 2021. The offering will be underwritten by a syndicate including Jefferies, Evercore ISI, and RBC Capital Markets. Funds raised will primarily support research and development, along with general corporate needs. Additionally, underwriters have a 30-day option to purchase an extra 3.75 million shares.
BELLUS Health (BLU) announced a proposed public offering of common shares totaling US$175 million. This follows a preliminary prospectus supplement filed with Canadian securities authorities and the SEC. The net proceeds are intended for research and development, administrative expenses, and working capital. Underwriters will have a 30-day option to purchase an additional 15% of shares offered. The offering's pricing will be determined based on market conditions, with customary closing conditions, including TSX approval.
BELLUS Health announced significant results from its Phase 2b SOOTHE trial of BLU-5937 for treating refractory chronic cough (RCC). The trial revealed a 34% placebo-adjusted reduction in 24-hour cough frequency at both 50 mg and 200 mg BID doses (p ≤ 0.005). BLU-5937 showed favorable tolerability with a low rate of taste-related adverse events (6.5%). The company plans to discuss the Phase 3 program with the in 2Q 2022. However, the Phase 2a BLUEPRINT trial for chronic pruritus did not achieve statistical significance.